A change in HER2 status relative to the status at primary diagnosis can be expected in approximately 10% of metastatic tumors, with loss of expression observed in most cases (change from HER2-positive to HER2-negative) [25]. The gene discussed is ERBB2; the disease is metastatic neoplasm.